ArticleFrontiers in cellular and infection microbiology2026
Development and validation of a prognostic nomogram model for 28-day mortality based on IP-10 and clinical parameters in septic patients in the emergency department.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early identification and precise prognosis of sepsis are of great significance. Traditional biomarkers, such as procalcitonin (PCT) and lactate (Lac), do not reflect the immune dysregulation at the center of sepsis pathophysiology. Interferon - γ -induced protein 10 (IP-10) is an important chemokine for septic immune dysregulation responses and may have good predictive value. Our research aims to establish and validate a clinically applicable nomogram that combines IP-10 and conventional clinical parameters to predict the 28-day mortality in septic patients in the emergency department (ED). Methods: This study recruited 655 patients who met the criteria of sepsis 3.0 from the ED of Beijing Chao-Yang Hospital from November 2023 to May 2025. A total of 580 patients were analyzed and randomly divided into the training group and the validation group in a 7:3 ratio. The variable selection in this study was conducted using the Least Absolute Shrinkage and Selection Operator (LASSO) regression, and our research employed multivariate logistic regression to determine independent predictors of 28-day mortality. The study scientifically evaluated nomogram using receiver operating characteristic (ROC) curves, calibration plots, Decision Curve Analysis (DCA), and Clinical Impact Curves (CIC). Results: Among the 580 patients, the 28-day mortality rate was 12.9% (75 non-survivors). Multivariate analysis identified five independent risk factors: IP-10 (OR = 1.978, 95% CI: 1.964-1.992), Sequential Organ Failure Assessment (SOFA) score (OR = 1.526, 95% CI: 1.365-1.758), Lac (OR = 1.447, 95% CI: 1.281-1.711), PCT (OR = 1.562, 95% CI: 1.341-1.924), and Acute Physiology and Chronic Health Evaluation II (APACHE II) score (OR = 1.658, 95% CI: 1.515-1.840). The nomogram showed excellent discriminatory ability. The area under the curve (AUC) of the training set and validation set was 0.952 (95% CI: 0.930-0.974) and 0.946 (95% CI: 0.911-0.981), respectively. Calibration was satisfactory, and DCA/CIC analyses confirmed that within the risk threshold range, the clinical net benefit was significant. Conclusion: It is the first time to develop and validate a prognostic nomogram model for 28-day mortality based on IP-10 and clinical parameters in septic patients in the ED. This tool may assist clinicians in early risk stratification and clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.